Department of Molecular Oncology


Department head: Ragnhild A. Lothe, Professor
Department administrative consultants: Mona Hagen and Linda Uv Mjøen
Lab manager: Guro E. Lind

Research groups:

Genetics Genome Biology Epigenetics

Ragnhild A. Lothe Rolf I. Skotheim Guro E. Lind

Project group:

Cell signalling

Edward Leithe


Centre for Cancer Biomedicine    

Centre for Cancer Biomedicine

A Norwegian Centre of Excellence funded by the Research Council of Norway.


The K.G. Jebsen Colorectal Cancer Research Centre.




Norwegian Cancer Genomics Consortium


Latest News


Ragnhild A. Lothe and Michael Bretthauer substantially supported by FRIPRO

Lothe and Bretthauer
Lothe and Bretthauer

The Research Council of Norway and Norway’s research institutions are providing a total of NOK 1 billion to 46 FRIPRO Toppforsk projects (FRIPRO - "Frie prosjektmidler"). Each project will receive NOK 15–25 million over a four-to-five-year period.
FRIPRO is an open competitive arena for all research areas and disciplines, where there are no thematic guidelines and no requirements relating to the applicability or immediate utility of the research. The competition in FRIPRO is tough, and only the best researchers with particularly good projects and very well-written proposals have a chance at succeeding.
University of Oslo and Oslo University Hospital based research groups led by Ragnhild A. Lothe from the Department of Molecular Oncology and Michael Bretthauer from the Department of Transplantation Medicine are among the successful applicants. 


Ceremony Friday November 20th

Ragnar Mørk legacy prize 2015 to Guro E. Lind

From the ceremony:<br> Guro E. Lind and Harald A. Stenmark (photo Chema Bassols)
From the ceremony:
Guro E. Lind and Harald A. Stenmark (photo Chema Bassols)

The 2015 "Dr. Ragnar Mørk's legacy prize" went to Guro E. Lind, head of the Epigenetics Group at the Department of Molecular Oncology. This award of NOK 200.000 is annually given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research. The ceremony took place on Friday November 20th in the Research Building at Montebello. Guro E. Lind gave a lecture about the research activities that has earned her the award.
Guro E. Lind receives Dr. Ragnar Mørk's prize for 2015 for her outstanding research on cancer epigenetics, which has led to identification of several novel biomarkers in colorectal cancer, bladder cancer, ovarian cancer,  lymphoma and cholangiocarcinoma. These biomarkers may form the basis for diagnostic tests for early detection of cancer.

Photos from the ceremony  

Group leader Guro E. Lind appointed leader of the newly established Young Academy of Norway


20 young scientists have been selected from 160 applicants to become the founding members of the Young Academy of Norway. Read more at the YA web site and by following the links below.

From Forskerforum:
Overveldende respons for ungt akademi

From Uniforum:
Norge får akademi for unge forskere

From The Norwegian Academy of Science and Letters:
Akademiet for yngre forskere etableres

Akademiet for yngre forskere etableres (including blog)


Review article in Oncogene on alternative splicing in cancer


Dr. Anita Sveen and co-workers recently published a review article about alternative splicing in cancer in the journal Oncogene. In this article, an overview of known aberrant splicing events in cancer-critical genes and their potential as cancer biomarkers is given. The article also discusses cancer-associated patterns of splicing on a genome-wide scale. Furthermore, the genes encoding splicing factors are found to be enriched for cancer-critical somatic mutations and to have dysregulated expression patterns. Several novel cancer-critical splicing factors are proposed. Sveen has previously investigated the biomarker potential of aberrant splicing events in cancer (Sveen et al., Int J Cancer 2012;131:1479-85) and identified transcriptome instability, TIN, in colorectal cancer as a splicing-related molecular feature that is associated with splicing factor gene expression levels and poor patient survival (Sveen et al., Genome Med 2011;3:32 and BMC Genomics 2014;15:672). Sveen is currently a post doc in the Lothe group, working with genomics of colorectal cancer in a translational research perspective.

Link to article:

Link to the Genetics Group in the Department of  Molecular Oncology:

Link to the K.G. Jebsen Colorectal Cancer Research Centre:


Contact information

Department of Molecular Oncology, Institute for Cancer Research
Oslo University Hospital HE - Norwegian Radium Hospital
Mail address: P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway
Street address: Norwegian Radium Hospital, Montebello
Phone: +47 2278 1728, Switchboard: +47 2293 4000, Fax: +47 2278 1745